1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Shanghai Haohai Biological Technology Co., Ltd.

Shanghai Haohai Biological Technology Co., Ltd.

688366.SS
Shanghai Haohai Biological Technology Co., Ltd.CN flagShanghai Stock Exchange
31.30
CNY
+0.71
- -
5.95BMarket Cap
Shanghai Haohai Biological Technology Co., Ltd.
688366.SS
(Shanghai Stock Exchange)

Recent

price

31.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.93
3.23
3.8
6
6.9
6.99
5.34
7.1
8.66
11.04
11.5
10.55
- -
Revenue per Share
1.04
1.33
1.36
1.66
1.85
1.62
0.93
1.43
0.74
1.74
1.8
1.08
- -
Basic EPS, GAAP
0.27
0.96
0.8
0.93
1.07
-0.22
0.27
0.28
-0.35
1.54
1.22
1.31
- -
Free Cash Flow per Basic Share
0.4
0.24
0.26
0.38
0.36
0.35
0.5
0.36
0.5
0.29
1.11
0.99
- -
Dividend per Share
3.06
4.04
4.71
5.98
7.67
8.87
0.71
10.08
10.47
12.15
13.29
13.52
- -
Book Value per Share
3.17
12.78
10.57
11.44
13.55
20.62
19.22
19.75
19.37
20.42
20.54
20.68
- -
Tangible Book Value per Share
176
206
224
224
224
228
248
247
243
239
233
232
229
Basic Weighted Avg Shares
516
664
851
1,345
1,546
1,595
1,324
1,750
2,103
2,635
2,680
2,446
- -
Sales/Revenue/Turnover
41.31
38.06
36.43
30.9
24.5
21.85
9.46
13
10.47
16.64
16.65
12.96
- -
Operating Margin (%)
23
34
36
68
84
115
133
163
204
198
205
207
- -
Depreciation Expense
184
273
305
372
415
371
230
352
180
416
420
251
- -
Net Income, GAAP
14.86
14.76
15.1
13.35
13.35
13.35
11.94
9.24
19.26
18.89
19.29
12.93
- -
Effective Tax Rate (%)
35.58
41.19
35.84
27.69
26.82
23.24
17.37
20.13
8.58
15.79
15.69
10.26
- -
Profit Margin (%)
208
2,231
1,952
1,908
1,843
3,585
3,376
3,225
3,021
3,034
2,792
2,548
- -
Working Capital
- -
- -
- -
18
16
24
20
39
84
191
143
64
- -
LT Debt
594
2,665
2,986
3,385
3,835
5,653
5,734
6,060
5,902
6,017
5,917
5,605
- -
Total Equity
- -
12.95
9.11
11.02
8.93
6.29
1.91
3.44
2.92
5.7
5.62
4.46
- -
Return on Invested Capital (%)
- -
39.86
29.99
25.45
21.24
17.36
17
20.87
5.9
12.67
12.67
8.16
- -
Return on Capital (%)
- -
39.94
32.34
31.12
27.12
19.81
20.9
26.46
7.18
15.29
14.02
8.06
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Mar'26
ST Debt
10
231
- -
LT Borrowings
173
167
- -
LT Finance Leases
30
26
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
236
235
- -
Market Capitalization
16,618
14,568
8,878

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Mar'26
Total Current Assets
3,745
3,720
- -
Cash, Cash Equivalents & STI
2,727
2,738
- -
Accounts Receivable, Net
329
336
- -
Inventories
534
504
- -
Total Current Liabilities
690
808
- -
Payables & Accruals
- -
- -
- -
ST Debt
10
231
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.56%
-0.38%
-5.28%
Free Cash Flow
-109.07%
-151.96%
6.65%
Net Income, GAAP
9.21%
19.13%
-40.3%
Sales/Revenue/Turnover
15.79%
14.12%
-8.71%
Total Cash Common Dividend
- -
46.6%
-11.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
646
758
- -
- -
2,680
2025
- -
- -
- -
- -
2,446
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
- -
- -
- -
1.8
2025
- -
- -
- -
- -
1.08
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.11
2025
- -
- -
- -
- -
0.99
2026
- -
- -
- -
- -
- -
Similar Companies
Canton Strategic Holdings Inc (CNTN)
Oncocross Co., Ltd. (382150.KQ)
Molecular Templates, Inc. (MTEM)
Innate Pharma S.A. (IPHYF)
BioVaxys Technology Corp. (BIOV.CN)
Apexigen, Inc. (APGNW)
Business
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials and biological products. Its main product portfolio includes ophthalmology products such as intraocular lenses, medical sodium hyaluronate gel, and lubricant eye drops; orthopedics products including sodium hyaluronate injection, medical chitosan, and medical sodium hyaluronate gel; medical aesthetics and wound care products featuring recombinant human epidermal growth factor and hyaluronic acid-based dermal fillers and gels; as well as anti-adhesion and hemostasis products like medical collagen sponges. The company also provides biological reagents, instruments, and related technology transfer and consultation services. Founded in 2007 and headquartered in Shanghai, China, Shanghai Haohai Biological Technology operates primarily in Mainland China with emerging global reach including Europe and the United States. Recent major developments include the successful approval in July 2024 of "Haimi Yuebai," the first globally organic cross-linked high-end hyaluronic acid product characterized by precise sculpting capabilities, marking an advancement into the high-end medical aesthetics market. The company has also expanded its medical aesthetics business through key acquisitions and investments, such as the acquisition of a full stake in a lens manufacturing unit in 2024, bolstering its ophthalmology product line. Additionally, it maintains strategic partnerships with academic institutions and distributors, enhancing R&D and market penetration. Shanghai Haohai continues to focus on innovation in bioengineering, ophthalmology, medical aesthetics, and orthopedics while navigating industry regulatory compliance and expanding its international footprint.